A case report of focused ultrasound neuromodulation of the bilateral nucleus accumbens for methamphetamine use disorder.
James J Mahoney, Daisy G Y Thompson-Lake, Manish Ranjan...
https://pubmed.ncbi.nlm.nih.gov/40892597/Actively Recruiting
Led by InSightec · Updated on 2026-06-26
29
Participants Needed
4
Research Sites
52 weeks
Total Duration
Researchers are evaluating the use of Low Intensity Focused Ultrasound LIFU with the Exablate4000 Type 2.02.1 device as an additional neuromodulatory treatment for Opioid Use Disorder OUD and other Substance Use Disorders SUDs. The study focuses on assessing the safety and tolerability of this treatment in people with OUD. This clinical trial is designed to explore how this device may help manage these conditions. Participants will undergo two treatment stages. In each stage, they will receive both a sham inactive and an active LIFU treatment, but they will not know which one they receive first. The first stage involves a moderate intensity LIFU procedure, while the second stage uses an enhanced intensity procedure. After each treatment, participants will be monitored for 90 days to assess any adverse events. Throughout the study, participants will be evaluated regularly for treatment-emergent adverse events from the time of the Exablate procedure through a four-month follow-up period. They will need to comply with study visits and report their sensations during the procedure. Safety and tolerability will be closely monitored, with participants expected to complete all study visits and assessments. The total participation time includes treatment stages and follow-up, ending no later than 2027.
CONDITIONS
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
K
Kingsley Nwaogu
J
Julia Zhu
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
InSightec
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Exablate LIFU Neuromodulation Plus Standard Care | Current Standard Care (No Neuromodulation) |
|---|---|---|
| What it is | MRI-guided low-intensity focused ultrasound (LIFU) neuromodulation targeting the nucleus accumbens performed with the Exablate Model 4000 device, administered in addition to ongoing behavioral and medical therapy for opioid or other substance use disorders. | Current standard care includes structured behavioral interventions, medical management, and pharmacotherapy options such as buprenorphine, methadone, or naltrexone for opioid use disorder. Device-based neuromodulation is not part of standard care outside investigational settings. |
| Role in the trial | Assigned investigational intervention; all enrolled participants received both active and sham Exablate LIFU neuromodulation in staged procedures, in addition to their standard therapy. | Not directly studied in this trial; represents the standard treatment pathway outside clinical trials for otherwise eligible patients. |
| Primary use | Investigational adjunctive therapy intended to modulate brain circuits involved in addiction and support sustained recovery when added to standard care for opioid or other substance use disorders. | Behavioral therapies, counseling, medical management, and pharmacotherapy provide evidence-based treatment for opioid and other substance use disorders, improving abstinence rates and reducing relapse and overdose risk. |
| How it is given or performed | Participants undergo MRI-guided Exablate LIFU neuromodulation in two stages: Stage 1 (moderate intensity), Stage 2 (enhanced intensity), with both sham and active procedures, under supervision and following detailed eligibility screening. All participants continue standard therapy throughout. | Standard care is delivered via outpatient, inpatient, or residential programs, typically involving structured counseling, cognitive and behavioral therapies, and, when indicated, medications for opioid or alcohol use disorder under medical supervision. |
| Evidence status | Human clinical evidence for Exablate LIFU neuromodulation in substance use disorders is limited. Published data include only case reports and small early-phase studies; efficacy, safety, and real-world impact remain unestablished for this approach. | Multiple randomized trials and high-quality evidence demonstrate the effectiveness of behavioral therapies and approved medications in improving outcomes and reducing relapse risk in opioid and other substance use disorders. |
| Important limitations | Main limitations include the investigational status of LIFU for these conditions, minimal human data to date, unknown long-term effects, and lack of regulatory approval for addiction treatment. Participants undergo detailed selection and monitoring but real-world safety, tolerability, and benefit are not established. | Standard medical and behavioral treatments may not achieve sustained abstinence in all individuals; relapse and ongoing support needs are common, and access to evidence-based therapies is sometimes limited by system-level barriers. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to 90 days post-treatment monitoring
Participants receive both sham and moderate intensity active Exablate LIFU treatments in a randomized order. They are monitored for sensations during the procedure.
Multiple visits during and after treatment for assessment
Duration - Up to 90 days post-treatment monitoring
Participants receive both sham and enhanced intensity active Exablate LIFU treatments in a randomized order. Monitoring for adverse events continues.
Multiple visits during and after treatment for assessment
Duration - 4 months
Participants are observed for any treatment-emergent adverse events through a four-month follow-up period after the final procedure.
Regular follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
James J Mahoney, Daisy G Y Thompson-Lake, Manish Ranjan...
https://pubmed.ncbi.nlm.nih.gov/40892597/InSightec
Lead Sponsor